These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33755097)

  • 1. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
    Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
    Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
    Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP
    J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
    Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
    Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
    Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Klevebro F; Alexandersson von Döbeln G; Wang N; Johnsen G; Jacobsen AB; Friesland S; Hatlevoll I; Glenjen NI; Lind P; Tsai JA; Lundell L; Nilsson M
    Ann Oncol; 2016 Apr; 27(4):660-7. PubMed ID: 26782957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evaluation of multimodal treatment practice in older oesophageal cancer patients.
    Shen T; Zhang Y; Cao Y; Zhang J; Li H
    Eur J Cardiothorac Surg; 2024 Oct; 66(4):. PubMed ID: 39298505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer.
    Bekkar S; Gronnier C; Renaud F; Duhamel A; Pasquer A; Théreaux J; Gagnière J; Meunier B; Collet D; Mariette C;
    Br J Surg; 2016 Jun; 103(7):855-62. PubMed ID: 27040445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma.
    Cools-Lartigue J; Markar S; Mueller C; Hofstetter W; Nilsson M; Ilonen I; Soderstrom H; Rasanen J; Gisbertz S; Hanna GB; Elliott J; Reynolds J; Kisiel A; Griffiths E; Van Berge Henegouwen M; Ferri L
    Ann Surg; 2022 Nov; 276(5):799-805. PubMed ID: 35861351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
    Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
    Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
    Sunde B; Klevebro F; Johar A; Johnsen G; Jacobsen AB; Glenjen NI; Friesland S; Lindblad M; Ajengui A; Lundell L; Lagergren P; Nilsson M
    Br J Surg; 2019 Oct; 106(11):1452-1463. PubMed ID: 31436322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.